#1 Clinical Trials Search in Europe

Nizaracianine Triflutate

This article discusses the clinical trials of Nizaracianine Triflutate, a novel drug designed to improve ureter visualization during abdominopelvic surgery. The trials aim to assess the drug’s safety and effectiveness in helping surgeons identify and avoid damaging the ureters, which are often difficult to see during surgical procedures. The study, known as TRIPHASE, is divided into three phases and involves testing different doses, comparing the drug to a placebo, and evaluating its performance in various surgical scenarios.

Table of Contents

What is Nizaracianine Triflutate?

Nizaracianine Triflutate, also known as ZW800-1, is a new drug being studied to help surgeons during certain types of operations[1]. It’s not a medicine to treat a specific disease, but rather a tool to help doctors see important parts of the body more clearly during surgery.

Purpose of the Drug

The main purpose of Nizaracianine Triflutate is to help surgeons see and avoid damaging the ureters during abdominopelvic surgery[1]. Ureters are thin tubes that carry urine from the kidneys to the bladder. They can be hard to see during surgery and are sometimes accidentally injured, which can lead to serious complications.

This drug is being tested to see if it can:

  • Make the ureters easier to see during surgery
  • Show how well the ureters are working in real-time
  • Reduce the risk of accidental injury to the ureters
  • Help surgeons identify and repair any damage to the ureters more quickly

How It Works

Nizaracianine Triflutate is a special type of molecule that has some unique properties[1]:

  1. It’s given to patients through an injection into their veins.
  2. The drug doesn’t stick to other tissues in the body, which helps it move quickly to the kidneys.
  3. The kidneys filter the drug out of the blood and into the urine.
  4. As the urine flows through the ureters, it carries the drug with it.
  5. When surgeons use a special camera that can detect near-infrared (NIR) light, they can see the drug glowing in the ureters.

This glow helps surgeons see where the ureters are located and how well they’re working, without having to cut or move other tissues out of the way[1].

Clinical Trial Overview

Researchers are conducting a clinical trial called TRIPHASE to test Nizaracianine Triflutate[1]. The trial is divided into three parts:

  1. Phase 2: This part tests different doses of the drug in 36 patients to find the best dose.
  2. Phase 3A: This part compares the best dose from Phase 2 to a placebo (a harmless sugar solution) in 100 patients.
  3. Phase 3B: This final part gives the best dose to 200 patients and compares how well surgeons can see the ureters with and without the drug.

During the trial, patients may receive up to three doses of the drug during their surgery, with at least 60 minutes between each dose[1].

Potential Benefits

If Nizaracianine Triflutate works as hoped, it could provide several benefits for patients and surgeons[1]:

  • Faster identification of ureters during surgery
  • Less need for invasive procedures to find the ureters
  • Reduced risk of accidental injury to the ureters
  • Quicker detection and repair of any ureter damage
  • Potentially shorter surgery times
  • Improved outcomes for patients, especially women and those in non-urban areas

Safety Considerations

As with any new drug, the safety of Nizaracianine Triflutate is being closely monitored throughout the clinical trial[1]. The researchers are checking for any side effects or unexpected reactions to the drug. It’s important to note that this drug is still being studied and is not yet approved for general use. Patients who participate in the trial will be carefully monitored and informed about any potential risks.

Aspect Details
Drug Name Nizaracianine Triflutate (ZW800-1)
Purpose Enhance ureter visualization during abdominopelvic surgery
Trial Name TRIPHASE
Trial Structure Phase 2/3 randomized controlled semi-blinded trial
Trial Phases Phase 2: Dose testing, Phase 3A: Drug vs. Placebo, Phase 3B: All receive drug
Administration Up to 3 intravenous bolus injections, 60 minutes apart
Primary Outcome Successful ureter identification by surgeons
Secondary Outcomes Reduced invasive procedures, faster identification, improved integrity assessment
Potential Benefits Reduced ureter injury, shorter surgery times, improved patient outcomes

FAQ

  • What is Nizaracianine Triflutate and how does it work? Nizaracianine Triflutate, also known as ZW800-1, is a new drug that helps surgeons see the ureters during abdominopelvic surgery. It is injected into the patient's bloodstream and is filtered by the kidneys into the urine. This makes the ureters visible when viewed with a special near-infrared camera, helping surgeons avoid accidental injury.
  • Why is visualizing the ureters important during surgery? Visualizing the ureters is crucial because they are thin-walled, collapsible tubes that are difficult to see during surgery. Accidental damage to the ureters can lead to serious complications, including fever, abdominal pain, and infections. By making the ureters more visible, surgeons can reduce the risk of injury and improve patient outcomes.
  • How is the clinical trial for Nizaracianine Triflutate structured? The clinical trial, called TRIPHASE, is divided into three parts: Phase 2 tests different doses to determine the best one, Phase 3A compares the drug to a placebo, and Phase 3B administers the drug to all participants to gather more data on its effectiveness.
  • What are the main goals of the Nizaracianine Triflutate clinical trial? The main goals of the trial are to determine if Nizaracianine Triflutate is safe for use in patients undergoing abdominopelvic surgery and if it can effectively help surgeons see the ureters while also providing information about how well they are functioning.
  • Who might benefit from this new drug if it proves successful? If successful, Nizaracianine Triflutate could benefit patients undergoing abdominopelvic surgeries, particularly women who are at higher risk of ureter injury during gynecological procedures. It could also help less experienced surgeons and those in non-urban settings to reduce the risk of ureter damage during surgery.

Ongoing Clinical Trials on Nizaracianine Triflutate

  • Study on Ureter Imaging with Nizaracianine Triflutate for Patients 18+ Undergoing Abdominopelvic Surgery

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Ureters: Thin-walled, collapsible tubes that connect the kidneys to the bladder, carrying urine from the kidneys to be expelled from the body.
  • Abdominopelvic surgery: Surgical procedures performed in the abdominal and pelvic areas of the body.
  • Nizaracianine Triflutate: A novel drug (also known as ZW800-1) designed to enhance visualization of the ureters during surgery by creating a visual contrast when viewed with a near-infrared camera.
  • Near-infrared (NIR) camera: A special camera that can detect near-infrared light, used in this case to visualize the ureters after administration of Nizaracianine Triflutate.
  • Iatrogenic damage: Unintended harm or injury caused by medical treatment or procedures.
  • Placebo: An inactive substance (in this case, sugar) given to some participants in a clinical trial to compare its effects with the active drug being tested.
  • Signal-to-background ratio (SBR): A measure used to determine how well the ureters can be distinguished from surrounding tissues when using Nizaracianine Triflutate.
  • Ureter skeletonization: A surgical technique involving careful dissection around the ureter to expose it fully, which may be reduced or eliminated with the use of Nizaracianine Triflutate.
  • Intraoperative: Occurring or performed during a surgical operation.
  • Zwitterionic: A chemical structure that contains both positively and negatively charged groups, which helps Nizaracianine Triflutate avoid binding to tissues non-specifically and facilitates its excretion by the kidneys.

References

  1. https://clinicaltrials.gov/study/NCT06101745